RxDoctor Payments Data

Laura Reed

Primary Care · Memphis, TNNPI 1881719938

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,000 of the $1,480 with a category attached, or 67.6%. 10 manufacturers reported payments, led by Shield Therapeutics Inc at 32.4% of the total. Reporting peaked in 2022 at $1,113 and has fallen 97.5% since, to $27 in 2024.

$1,480in general payments, 2019–2025

Across 12 payments — averaging $123.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shield Therapeutics Inc$480
  • Abbott$309
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$171
  • Teva Pharmaceuticals USA, Inc.$125
  • Bayer$117
  • Xeris Pharmaceuticals, Inc.$113
  • plus $166 from 4 others

What the payments were for

  • Speaking & faculty fees$48032%
  • Food & beverage$1,00068%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,480 in reported general payments places this provider in the 70th percentile of 189 primary care providers in Tennessee.

See all primary care providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,634
Medicare patients
11
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$23,774
Colchicine12$1,932
Montelukast Sodium29$463
Atorvastatin Calcium31$383
Albuterol Sulfate HfaAlbuterol Sulfate13$377
Allopurinol12$118
Metformin Hcl ErMetformin Hcl12$112
ClopidogrelClopidogrel Bisulfate12$79
Metformin Hcl15$75
Pantoprazole Sodium13$69
Amlodipine Besylate23$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$92$23,77422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 189 primary care providers in Tennessee.

Other primary care in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →